» Articles » PMID: 15934985

Intraoperative Blood Loss During Living Donor Liver Transplantation: an Analysis of 635 Recipients at a Single Center

Overview
Journal Transfusion
Specialty Hematology
Date 2005 Jun 7
PMID 15934985
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Living-donor liver transplantation (LDLT) has been an important option in the treatment of patients with end-stage liver disease. Massive intraoperative blood loss can occur during LDLT, necessitating blood transfusion. The purpose of this study was to present blood loss data from the recipients of LDLT, to assess the effect of massive intraoperative blood loss on prognosis, and to assess the reliability of preoperative information in predicting intraoperative blood transfusion requirements in LDLT.

Study Design And Methods: A total of 635 patients who underwent LDLTs between January 1995 and March 2002 at a university hospital were retro- spectively investigated. The volume of blood loss, prognosis, and preoperative variables were analyzed statistically.

Results: Intraoperative blood loss ranged from 5.15 to 1980 mL per kg (mean, 136 mL/kg). Massive blood loss negatively affected survival not only immediately after operation (high blood loss [HBL]:low blood loss [LBL] ratio, 85.5%:93.9% at 1 month) but also over the long term (HBL:LBL, 61.4%:76.8% at 5 years). Preoperative risk factors for massive blood loss were determined to be recipient age (<1 years), weight (<10 kg), C-reactive protein (>2 mg/dL), hematocrit (<30%), total bilirubin (>20.0 mg/dL), direct bilirubin (>16.0 mg/dL), and blood urea nitrogen levels (>30.0 mg/dL).

Conclusions: The risk factors associated with massive intraoperative blood loss during LDLT were identified. This is the first analysis of blood loss during LDLT at a single center. Massive blood loss is a predictor of poor prognosis in LDLT patients.

Citing Articles

A single center analysis of long-term outcomes and survival related risk factors in liver retransplantation.

Li Z, Sng Y, Chen C, Lin C, Wang S, Yong C Hepatobiliary Surg Nutr. 2024; 13(3):425-443.

PMID: 38911194 PMC: 11190508. DOI: 10.21037/hbsn-23-178.


High-dose ulinastatin to prevent late-onset acute renal failure after orthotopic liver transplantation.

Lv H, Wei X, Yi X, Liu J, Lu P, Zhou M Ren Fail. 2020; 42(1):137-145.

PMID: 31984833 PMC: 7034081. DOI: 10.1080/0886022X.2020.1717530.


Association between viscoelastic tests-guided therapy with synthetic factor concentrates and allogenic blood transfusion in liver transplantation: a before-after study.

Zamper R, Amorim T, Queiroz V, Lira J, Costa L, Takaoka F BMC Anesthesiol. 2018; 18(1):198.

PMID: 30579327 PMC: 6303918. DOI: 10.1186/s12871-018-0664-8.


Clinical Beneficial Effects of Using Crystalloid only in Recipients of Living Donor Liver Transplantation.

Huang C, Cheng K, Chen C, Wu S, Shih T, Yang S Int J Environ Res Public Health. 2017; 14(11).

PMID: 29156640 PMC: 5708057. DOI: 10.3390/ijerph14111418.


Massive haemorrhage in liver transplantation: Consequences, prediction and management.

Cleland S, Corredor C, Ye J, Srinivas C, McCluskey S World J Transplant. 2016; 6(2):291-305.

PMID: 27358774 PMC: 4919733. DOI: 10.5500/wjt.v6.i2.291.